1825P Molecular features of circulating tumour cells (CTCs) associate with response to 177Lu-PSMA-617 plus pembrolizumab for metastatic castration resistant prostate cancer (mCRPC) — David L. Goode (2023) | RDL Network
1825P Molecular features of circulating tumour cells (CTCs) associate with response to 177Lu-PSMA-617 plus pembrolizumab for metastatic castration resistant prostate cancer (mCRPC)
Anis Hamid, Michael S. Hofman, Mathias Bressel, Louise Emmett, Anthony M. Joshua, Lavinia Spain, Lisa G. Horvath, Megan Crumbaker, Anupama Pasam, Jason Callahan, Alisa Tubbs, Luisa Fernandez, Richard Wenstrup, Grace Kong, Jeremy Lewin, Ben Tran, Arun Azad, Joseph D. Schonhoft, Rodney J. Hicks, Shahneen Sandhu
Shahneen Sandhu, Anthony M. Joshua, Louise Emmett, Lavinia Spain, Lisa G. Horvath, Megan Crumbaker, A. Antón, Roslyn Wallace, Anupama Pasam, Mathias Bressel, E. Cassidy, Patricia Banks, Aravind Ravi Kumar, Ramin Alipour, Timothy Akhurst, Grace Kong, Ian D. Davis, Scott Williams, Rodney J. Hicks, Michael S. Hofman
Shahneen Sandhu, Anthony M. Joshua, Louise Emmett, Megan Crumbaker, Mathias Bressel, Rhonda Huynh, Patricia Banks, Roslyn Wallace, Anis Hamid, Andrisha Jade Inderjeeth, Ben Tran, Arun Azad, Ramin Alipour, Grace Kong, Aravind Ravi Kumar, Javad Saghebi, Scott Williams, Timothy Akhurst, Rodney J. Hicks, Michael S. Hofman
Justin Ferdinandus, John Violet, Shahneen Sandhu, Rodney J. Hicks, Aravind S. Ravi Kumar, Amir Iravani, Grace Kong, Tim Akhurst, Sue Ping Thang, Declan G. Murphy, Scott Williams, Michael S. Hofman
Heidi Fettke, Louise Kostos, James Buteau, Jason A. Steen, Elizabeth Medhurst, Mo B. Haskali, Declan G. Murphy, Maria Docanto, Patricia Bukczynska, Nicole Ng, Shahneen Sandhu, Siavash Foroughi, Luc Furic, Tú Nguyen‐Dumont, Michael S. Hofman, Arun Azad
Discussion(0)
No comments yet. Be the first to comment.